Synthesis and study of new local cancer cell inhibitors with consideration of antiproliferative activity and toxicity

Programme

"STIMULATING EXCELLENCE IN RESEARCH FOR 2024-2025"

Strategic priority

I. Health

Code
24.80012.8007.01SE
Duration
2024-2025
Institutions

Institute of Chemistry of MSU

Project manager
Results, activities

Summary of the activity and results obtained in 2024

The direction involving the creation of new pharmaceutical products from local (autochthonous) resources covers a wide range of interdisciplinary fields where chemistry, physics, biology and medicine intersect. Cancer therapy is a highly significant area that is developing rapidly. This field is associated with the use of modern scientific technologies and opens up new perspectives in personalized cancer treatment, chemotherapy and the development of effective treatment schemes. The main idea of ​​the project is to synthesize new molecular cancer inhibitors with high activity and increased selectivity at micro- and nano-molar concentrations, as well as to study the molecular mechanism of action of antitumor drugs. New specific strategies and methods for the chemical synthesis of organic molecules and coordination compounds of biometals were developed to obtain a new generation of molecular inhibitors of cancer cell proliferation. The antiproliferative activity of the tested compounds was studied in relation to cancer cells (cervical cancer, pancreatic cancer, rhabdomyosarcoma). Since the development of less toxic drugs targeting normal cells remains a critical aspect of cancer chemotherapy, substances were investigated in relation to normal dog kidney cells (MDCK) . Subsequently, a selectivity index was calculated.

Summary of the activity and results obtained in 2025

The direction involving the creation of new pharmaceuticals from local (autochthonous) resources covers a wide range of interdisciplinary fields where chemistry, physics, biology, and medicine intersect. Cancer therapy is a highly significant area that is developing rapidly. This field is associated with the use of modern scientific technologies and opens up new perspectives in personalized cancer treatment, chemotherapy, and the development of effective treatment schemes. The main idea of the project is to synthesize new molecular cancer inhibitors with high activity and increased selectivity at micro- and nano- molar concentrations, as well as to study the molecular mechanism of action of antitumor drugs. The optimal conditions for the synthesis of 12 4-allylthiosemicarbazone 2-hydroxy-benzaldehydes and substituted 2-formylpyridines, as well as 18 coordination compounds of copper, nickel and cobalt with these azomethines were found. New specific strategies and methods for the chemical synthesis of organic molecules and coordinative compounds of biometals will be  developed to obtain a new generation of molecular inhibitors of cancer cell proliferation. The antiproliferative activity of the tested compounds will be studied in relation to cancer cells (cervical cancer, pancreatic cancer, rhabdomyosarcoma). Since the development of less toxic drugs targeting normal cells remains a critical aspect of cancer chemotherapy, substances will be investigated in relation to normal dog kidney cells (MDCK). Subsequently, a selectivity index will be calculated. The selectivity index was calculated, which in the case of most of the investigated compounds falls within the range of 20-160 and has low toxicity.

Publications

Monograph

  1. GARBUZ, O., TODERAS, I., GULEA, A. Biological properties of some synthetic and natural compounds. Correlation of anticancer and antioxidant activities. Monograph. Tipografia Centrală. 271 p. Chisinau, 2024. ISBN 978-5-88554-387-3. https://www.bookchamber.md/carti-in-curs-de-aparitie-noiembrie-2024/
     

Article in international journal

  1. GARBUZ, O.; CEBAN, E.; ISTRATI, D.; RAILEAN, N.; TODERAS, I.; GULEA, A. Thiosemicarbazone-Based Compounds: Cancer Cell Inhibitors with Antioxidant Properties. Molecules 2025, 30, 2077. https://doi.org/10.3390/molecules30092077 (Q1, IF 4)
  2. RUSNAC, R.; GARBUZ, O.; KRAVTSOV, V.; MELNIC, E.; ISTRATI, D.; TSAPKOV, V.; POIRIER, D.; GULEA, A. Novel Copper(II) Coordination Compounds Containing Pyridine Derivatives of N4-Methoxyphenyl-Thiosemicarbazones with Selective Anticancer Activity. Molecules 2024, 29, 6002. https://doi.org/10.3390/molecules29246002 (Q1, IF4)
  3. GARBUZ, O., GRAUR, V., GRAUR, I., RAILEAN, N., TODERAS, I., PAHONTU, E., CEBAN, I., JINGA, V., ISTRATI, D., CEBAN, E., GULEA, A. Biological Activity of Copper(II) Complex (2-((2-(Prop-2-En-1- Ylcarbamothioyl) Hydrazinylidene)Methyl)-Phenolato)-ChloroCopper(II)         Monohydrate. In: Journal of Cancer Science and Clinical Therapeutics, 2024, 8 pp. 287-294. ISSN: 2637- 5079. https://www.doi.org/10.26502/jcsct.5079251

Abstratcts

  1. GULEA, Aurelian Desingn of molecules with strong anticancer properties PLENARY Session // International Congress MEDICINE, MOLECULAR AND ENVIRONMENTAL SCIENCES 2025, „From chemistry to medicine – 35 years of Moldo-Romanian scientific collaboration”. November, 10-15 2025. Chisinau, Republic of Moldova. BOOK OF ABSTRACTS. p.12.  https://doi.org/10.19261/medmol25
  2. GARBUZ, Olga, RAILEAN, Nadejda, RUSNAC, Roman, ŢAPCOV, Victor, UNGUREANU, Laurenţia, TODERAŞ, Ion, GULEA, Aurelian. Proprietățile biologice și toxicitatea noilor complexe de Cupru(II) cu un tiosemicarbazon conținând un fragment de paracetamol. In: Patrimoniul cultural de ieri – implicaţii în dezvoltarea societăţii durabile de mâine, Ed. 8, 8-9 februarie 2024, Chişinău. Iași – Chișinău-Lviv: 2024, Ediția 9, pp. 169-170. ISSN 2558 – 894X.
  3. GARBUZ, O., TODERAȘ, I., RUSNAC, R., RAILEAN, N., TSAPKOV, V., GULEA A. Toxicity and biological activities of a Copper(II) Thiosemicarbazone Complex. In:Internetional zoological congress, ZoologyCon, 6-9 November 2024, p. 162. Bucuresti, Romania. https://travaux.pensoft.net/article/140643
  4.